PATENT CLAIM ANALYSIS

Application Number: 15874396
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "044000"]

Abstract:
The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.

Claim (Index 15):
The composition of  claim 1 , wherein the iRNA agent is ligated to one or more diagnostic compound, reporter group, cross-linking agent, nuclease-resistance conferring moiety, natural or unusual nucleobase, lipophilic molecule, cholesterol, lipid, lectin, steroid, uvaol, hecigenin, diosgenin, terpene, triterpene, sarsasapogenin, Friedelin, epifriedelanol-derivatized lithocholic acid, vitamin, carbohydrate, dextran, pullulan, chitin, chitosan, synthetic carbohydrate, Oligo Lactate 15-mer, natural polymer, low- or medium-molecular weight polymer, inulin, cyclodextrin, hyaluronic acid, protein, protein-binding agent, integrin-targeting molecule, epithelial receptor ligand, polycationic, peptide, polyamine, peptide mimic, and/or transferrin.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 86.0
- Lexical Diversity: 1.27273
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15260824', '12683146', '14729104', '12771614', '12771566']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8288810747445183
- 35 USC 102 Novelty (BERT): 0.5562166276002048
- Combined Prediction Score: 0.8016146300300869
- Mean Citation Score: 410.52154
- Max Citation Score: 416.51477
- Similarity Product: 409.769586713934

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test